-
-
-
-
-
-
-
Aptinyx (APTX) Phase 2b Study of NYX-2925 in Fibromyalgia Did Not Achieve Statistically Significant Separation from Placebo
-
-
-
-
-
-
-
Pre-Open Stock Movers 04/07: (SEED) (HPQ) (CDK) Higher; (APTX) (VAPO) (RAD) Lower (more...)
-
-
-
-
-
-
-
Aptinyx Hosts Virtual Portfolio Review Event to Showcase NYX-2925 in Chronic Pain and Provide Update on Clinical Development Programs
-
-
-
-
-
-
-
Aptinyx to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021
-
-
-
-
-
-
-
Aptinyx to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021
-
-
-
-
-
-
-
Aptinyx Announces Recommencement of Phase 2 Study of NYX-2925 in Patients With Painful Diabetic Peripheral Neuropathy
-
-
-
-
-
-
-
Aptinyx Announces Pricing of Public Offering of Common Stock
-
1,222,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

